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Immune and complement systems/infl ammatory response Different types of genetic technologies and approaches allow for the study and identification of different types of genetic variability in a disease. Here represented are the genes and genetic loci independently replicated as being associated with the development of Alzheimer's disease (AD). Genetic linkage analyses (blue area) of familial cases have led to the identification of causative mutations in three genes: APP, PSEN1, and PSEN2, as well the identification of a high-risk factor: the E4 allele of APOE. More recently, the development of whole-genome genotyping platforms has allowed for the study of the involvement of common variants with low risk in the disease (orange area). This has led to the identification of 21 new genetic loci by several independent genome-wide association studies (GWAS): CLU, PICALM, CR1, BIN1, CD33, ABCA7, MS4A6A and MS4A4E (represented here as MS4A), CD2AP, EPHA1, HLA-DRB5/DRB1, SORL1, PTK2B, SLC24A4, ZCWPW1, CELF1, FERMT2, CASS4, INPP5D, MEF2C , and NME8. Because of the way that these studies are designed, they only identify genetic regions associated with disease and not specific genes or variants. For this reason, if the significant single-nucleotide polymorphisms (SNPs) are intergenic or if the region contains more than one gene, the locus usually gets its name from the gene closest to the significant hit. Very few of these significant hits have a clear functional role in the disease, and because of this, follow-up work is currently underway to determine exactly which genetic variants are important for the disease and how they are exerting their effect.
The integration of recently developed sequencing technologies (whole-exome and whole-genome sequencing, green area) with genotyping data has allowed the identification of the first rare variant with intermediate risk for AD in TREM2. These findings have clearly pointed to the involvement of several biological pathways in the etiopathogenesis of AD, as the implicated genes and loci seem to not be independent from each other; instead, they seem to cluster in several biological pathways (represented by different colors in the table) .
The finding of mutations in APP (and at a later stage the recognition that presenilins function at the γ-secretase complex level) led to the establishment of the amyloid cascade hypothesis. This suggests that the dysregulation of APP is the initiating event in AD pathogenesis, subsequently leading to the aggregation of Aβ. Formation of neuritic plaques would initiate further pathological events, including the development of neurofibrillary tangles and disruption of synaptic connections, which would lead to a reduction in neurotransmitters, death of tangle-bearing neurons, and eventually dementia. The more recent pathway analyses of GWAS data have implicated other pathways as primary etiological events in the disease, with clear, significant overrepresentation of association signals in pathways related to cholesterol metabolism and the immune response.
Pleomorphic Risk, Exemplified by APP
This panel illustrates that, at the same locus, several disease-related genetic mechanisms may coexist, each influencing disease through different biological effects on a single gene. In this particular model, expression of a gene is positively correlated with risk shown by duplication mutations of the APP locus, which are known to cause AD. Several different coding mutations (all located in exons 16 and 17 of the APP gene, which encode the amyloid β region of the protein) have been identified as the cause of disease in mainly early onset familial cases. More recently, a protective mutation (p.A673T) has been described in Scandinavian population.
